Abstract: Bone morphogenetic proteins (BMP), in particular BMP-2, are the growth factors primarily responsible for osteoinduction. A knowledge of interactions between bone substitute materials and growth factor variants is crucial to designing bone substitutes with an ideal release profile. Here we compare glycosylated and non-glycosylated recombinant human bone morphogenetic protein-2 (rhBMP-2) either incorporated into a hydrolyzable polyethylene glycol (PEG) hydrogel developed as a slow release system or adsorbed to a deproteinized bovine bone matrix (DBBM), a clinically well-established bone substitute material. rhBMP-2 loaded materials were immersed in cell culture medium and rhBMP-2 concentration profiles in the supernatant were determined by an enzyme-linked immunosorbent assay. The corresponding biological activities were assessed in vitro by alkaline phosphatase activity assay. We show a strong affinity of rhBMP-2 for DBBM and reduced biological activity after its release from PEG hydrogels. Glycosylated rhBMP-2 was significantly less affected by the hydrogel and interacted significantly more strongly with DBBM than non-glycosylated rhBMP-2. We therefore question the combination of PEG hydrogels with DBBM as a rhBMP-2 delivery system over DBBM alone, since rhBMP-2 released from the hydrogel will be trapped by DBBM. Moreover, our results suggest that glycosylated rhBMP-2 is favorable in combination with PEG hydrogels, since its activity is better preserved, whereas in combination with DBBM non-glycosylated rhBMP-2 is favorable, benefiting from an initially higher concentration of free rhBMP-2. The corresponding biological activities were assessed in vitro by an alkaline phosphatase activity assay. We show a strong affinity of rhBMP-2 to DBBM and a reduced biological activity after its release from PEG hydrogels. Glycosylated rhBMP-2 was significantly less affected by hydrogels and interacted significantly stronger with DBBM than non-glycosylated rhBMP-2. We therefore question the combination of PEG hydrogels with DBBM as a rhBMP-2 delivery system over DBBM alone since rhBMP-2 released from the hydrogel will be trapped by DBBM.
Introduction
Bone has a unique capacity to heal itself without leaving a scar [1] . However, if a gap derived from an injury, disease or a surgical treatment reaches a critical size, the body is not able to repair the void on its own. For these critical-sized defects or when bone augmentation is required, a bone substitute is needed. The ideal material for a bone substitute provides a three-dimensional, mechanically stable structure, serves as a carrier for growth factors that enhance bone in-growth, contains living osteoblastic cells that are accepted by the body and should eventually be replaced by newly formed bone [2] [3] [4] . Autologous bone fulfills all of these criteria.
Unfortunately, its use has severe drawbacks, namely increased morbidity at the harvest site and limited supply [5] . Therefore, alternatives such as allografts, xenografts or alloplasts are used. However, none of them provide all the properties of autografts [6] .
Deproteinized bovine bone matrix (DBBM) is the gold standard off-the-shelf bone substitute material in dentistry [7] . It consists of the mineral phase of bovine bone, containing hydroxyapatite as the main component. DBBM is devoid of any organic material, therefore it is not as tough as natural bone and devoid of bone-inducing growth factors [8] , making its combination with bone-inducing growth factors advantageous [9] .
Bone morphogenetic proteins (BMPs), in particular BMP-2 and BMP-7, are the growth factors mainly responsible for osteoinduction [10] . They recruit and stimulate adult mesenchymal stem cells and preosteoblastic cells to migrate, proliferate and mature into osteoblasts [11, 12] . Currently, glycosylated Chinese hamster ovary (CHO)-expressed recombinant human BMP-2 (rhBMP-2) in combination with a collagen carrier (Infuse®, Medtronic Sofamor Danek, Memphis, Tennessee) is commercially available and approved by the Food and Drug Administration (FDA) and the European authorities for lumbar spine fusion and persisting long bone defects. Glycosylated rhBMP-2 is also approved for several dental applications [13] .
Non-glycosylated rhBMP-2 produced by the prokaryotic expression system using E.
coli, is an alternative that could substantially reduce production cost and the price for clinical application. Despite the fact that E. coli-derived proteins are nonglycosylated, the biological potential of non-glycosylated rhBMP-2 has been reported to have bone-inducing activity similar to the glycosylated form [14] [15] [16] [17] . In a human clinical trial, we demonstrated the efficacy of non-glycosylated rhBMP-2 in a bone augmentation procedure [9] .
Controlling the release profile of rhBMP-2 from carrier materials is crucial to deliver the minimal effective growth factor load needed for bone reconstruction. Analysis of BMP expression during fracture healing revealed that BMP-2 expression was upregulated early and was elevated for up to 30 days [18] . It is therefore of advantage to release rhBMP-2 over a time period of days to weeks rather than hours [19] . Rapid diffusion away from the implantation site into body fluids, premature degradation of the carrier material, and inactivation of rhBMP-2 due to unwanted interactions with the carrier materials may limit the effectiveness of rhBMP-2 [19] [20] [21] [22] [23] [24] .
An approach for a system composed of clinically evaluated materials that provides mechanical stability and allows sustained growth factor delivery is the combination of DBBM with hydrolysable polyethylene glycol (PEG) hydrogels [25] [26] [27] [28] [29] [30] . In such a system, the release profile of the growth factor is dependent on the physical binding strength to the hydrogel, the degradation characteristics of the hydrogel and the interaction of the applied growth factor with the DBBM. A tunable, hydrolysable PEG hydrogel system based on a Michael-type reaction between PEG chains functionalized with acrylate groups and thiol groups has been previously developed [31] . The PEG system has been evaluated in clinical studies [32] and it was recently demonstrated that improved bone formation can be achieved by entrapping rhBMP-2 as well as parathyroid hormone peptide in this hydrolysable synthetic matrix [25, 30] .
Considering the similar bioactivity of glycosylated and non-glycosylated rhBMP-2, understanding the differences in the release characteristics of these variants from the carrier materials and the effect of their interaction with the carrier materials on their bioactivity is crucial. This analysis would enable the development of a successful composite of these well-known materials that allows faster bone formation and more economical use of growth factors. We therefore investigated the differences between glycosylated and non-glycosylated rhBMP-2 in terms of their interactions with DBBM, hydrolysable PEG hydrogels, and the combination of these materials as well as the bioactivity of the released rhBMP-2 variants.
Materials and Methods

General Preparations
Non-glycosylated rhBMP-2 was expressed in E.coli and refolded as previously described [33] . Glycosylated rhBMP-2 was obtained from Genetics Institute Inc., Massachusetts, USA. Both rhBMP-2 variants were desalted by solvent exchange to 1 mM HCl using centrifugal filters (MWCO 10 kDa, Millipore, Zug, Switzerland).
rhBMP-2 solutions were sterilized using Millex-LG Sterilizing Filter Units (0.2 m, Millipore, Zug, Switzerland). The concentration of rhBMP-2 was determined by a Bradford assay (Thermo Fisher Scientific, Lausanne, Switzerland) and samples were diluted in 1 mM HCl to 1 µg/µl accordingly.
All following experiments were carried out under sterile conditions and all materials were sterilized by vapour sterilization (134 °C) in the central sterilization facilities of the University Hospital Zurich unless specified separately. All experiments were carried out at room temperature (room temperature varied between 20 and 25 °C) unless specified separately. All samples were prepared with both glycosylated and non-glycosylated rhBMP-2.
Preparation of Bone Substitute Components
Hydrolyzable mPEG hydrogels were formed by a Michael-type reaction between acrylate and thiol groups described earlier by Elbert, et al. [31] and prepared similarly to previous in vivo studies [25, 30] . 15 kDa 4arm PEG functionalized with an acrylate group at the end of each arm and 3. The volume of mPEG hydrogel was chosen to exactly cover the volume of the loose DBBM particles allowing a homogeneous distribution of DBBM in the hydrogel. The gelation reaction was allowed to take place for 30 min. In order to shorten the time periods for this study, the precursors were chosen for a final concentration of 3% (w/v) PEG allowing the mPEG hydrogel to hydrolyze completely after 3 days.
In order to adsorb rhBMP-2 to DBBM from solution, 25 mg of DBBM were mixed with 50 µl 1 mM HCl containing 2.5 µg rhBMP-2. The mixture was vortexed, briefly spun down (10600xg, 10s) in a centrifuge and incubated for 60 min. Samples were used immediately without removing the liquid from the adsorption procedure. For the adsorption of rhBMP-2 to DBBM via lyophilisation, 25 mg of DBBM were mixed with 50 µl 1 mM HCl containing 2.5 µg rhBMP-2. The mixture was vortexed, briefly spun down in a centrifuge (10600xg, 10s) and frozen immediately using liquid nitrogen.
Frozen samples were lyophilized overnight. Controls were prepared without the addition of rhBMP-2. The pH change of 1 mM HCl solution 1h after the immersion of DBBM was evaluated using the same ratio between DBBM and 1 mM HCl as for the sample preparation. The cumulative amount of released rhBMP-2 was calculated taking into account the removal and addition of 50 µl of fresh medium at each time point. All results were standardized to the positive controls (100%).
Determination of rhBMP-2 Concentration Profiles
Cell Culture Assays
Cell Stimulation
Glycosylated and non-glycosylated rhBMP-2 were tested for differences in their biological activity as well as for differences in their stability at 37 °C in vitro. Standard series (100 -1000 ng/ml) of both rhBMP-2 variants were prepared in cell culture medium. The stability in cell culture medium was determined by incubating rhBMP-2 at 37 °C in cell culture medium for 0, 3, 9, 15 and 30 days without cells. A premyoblastic cell line (C2C12, ATCC, Molsheim Cedex, France) was stimulated with the standard series and the samples prepared for the stability test and tested for alkaline phosphatase activity as described in section 2.4.3.
The biological activity of the rhBMP-2 variants released from bone substitute materials as described in section 2.3 as well as the impact of bone substitute material degradation products and growth factors on cell viability were tested by stimulating C2C12 cells. Cells were stimulated with cell culture medium supernatant from a 15 days release from bone substitute materials prepared as described in section 2.3. Stimulated cells were tested for their viability as described in section 2.4.2 and for their ALP activity as described in section 2.4.3.
Cell Viability
Cell viability was evaluated after 3 and 6 days of incubation at 37 °C and 5% CO 2 in a humidified atmosphere. Viability was determined by adding cell proliferation reagent WST-1 (Roche, Basel, Switzerland) to the cell culture medium at the concentration specified by the manufacturer. Cells were incubated in presence of the cell proliferation reagent for 45 min at 37 °C and 5 % CO 2. The resulting colour reaction was evaluated by measuring the optical density at 450 nm using a plate reader (Synergy HT, Biotek, Luzern, Switzerland).
Alkaline Phosphatase Activity
The biological activity of rhBMP-2 was determined via an assay for alkaline phosphatase (ALP) activity, an early marker for osteoblastic differentiation. ALP is expressed by mesenchymal progenitor cells exposed to rhBMP-2 and its activity therefore provides an appropriate functional assessment of the growth factors bioactivity [34] . In detail, C2C12 cells were stimulated for 6 days at 37 °C and 5 % CO 2 and were subsequently lysed using 0.56 M 2-Amino-2-methyl-1-propanol (SigmaAldrich, Buchs, Switzerland) (pH, 10 containing 0.2 % Triton X-100 (SigmaAldrich)). ALP activity in the lysis buffer was determined via the kinetics of a colour reaction based on the reduction of p-nitrophenyl phosphate (Sigma Aldrich) to p-nitrophenol. The DNA concentration of the lysate was determined using a PicoGreen assay (Invitrogen, Basel, Switzerland). Optical density of the pnitrophenol reaction (410 nm) and fluorescence of PicoGreen (ex = 480 nm, em = 520 nm) was detected with a plate reader (Synergy HT, Biotek, Luzern, Switzerland).
The determined ALP activity was adjusted to the total cell number by standardizing it to the DNA concentration. All results were standardized to the positive controls (100%).
Statistical Analysis
All experiments were carried out with a total number of 6 individual and independent samples for each condition (n=6), except for the ALP assay which was carried out with 12 independent samples (n=12). Each experiment was carried out twice.
Gaussian distribution of samples was confirmed by a Shapiro-Wilk test. A two-tailed, heteroscedastic t-test (P<0.05) was applied to determine whether or not there are statistically significant differences between concentrations and/or activity of glycosylated and non-glycosylated rhBMP-2 after 15 days of incubation. For the statistical analysis of the cell culture viability, repeated measures ANOVA and subsequent pairwise Student's t-test with corrected P-values according to Bonferroni were used to detect significant differences between samples devoid of growth factors, loaded with non-glycosylated or glycosylated rhBMP-2. and non-glycosylated (56 ± 5% of positive control) rhBMP-2 at day 15 for the mPEG controls.
Interaction of rhBMP-2 with DBBM
pH measurements showed that the pH of 1 mM HCl was neutralized by DBBM after 1h if mixed at a concentration of 500 mg/ml DBBM (data not shown). We did not find any significant difference in adsorption behavior of rhBMP-2 between immersion in 1 mM HCl containing rhBMP-2 and lyophilisation (data not shown). We therefore applied the adsorption procedure without lyophilization for loading DBBM with rhBMP-2. After 1h adsorption in 1 mM HCl and 1h incubation in cell culture medium, 30 ± 14% glycosylated rhBMP-2 and 32 ± 4% non-glycosylated rhBMP-2 were detected in the cell culture medium supernatant relative to the positive control. These levels dropped to 7 ± 3% glycosylated and 16 ± 7% non-glycosylated rhBMP-2 after 
Combination of mPEG hydrogel, DBBM and rhBMP-2
We detected strongly reduced concentrations of glycosylated and non-glycosylated did not find any significant differences.
Along with the measurement of the biological activity of rhBMP-2 (section 2.4), we determined the total amount of DNA of the stimulated cells by a PicoGreen assay.
After 6 days we found a significantly higher amount of DNA in samples containing glycosylated or non-glycosylated rhBMP-2, however we did not find any significant differences between samples containing glycosylated or non-glycosylated rhBMP-2 ( Figure 6 ). However, comparing the DNA content between samples stimulated with cell culture supernatant from bone substitute materials not containing rhBMP-2, we found a significant decrease for those samples containing mPEG hydrogels.
Biological Activity of rhBMP-2 -Impact of Bone Substitute Materials
The biological activity of glycosylated and non-glycosylated rhBMP-2 was tested by stimulating C2C12 cells with various concentrations of both growth variants and testing them for their ALP activity. We did not find any significant differences between glycosylated and non-glycosylated rhBMP-2 ( The impact of incubating rhBMP-2 together with bone substitute materials on the bioactivity of the growth factor was investigated by stimulating C2C12 cells with the cell culture supernatant from mPEG hydrogels, DBBM and DBBM in mPEG hydrogel and testing them for their ALP activity. Incorporation into mPEG hydrogels reduced the activity of rhBMP-2 in the cell culture medium supernatant. The activity of nonglycosylated rhBMP-2 (49 ± 6% of positive control) was reduced significantly more than the activity of the glycosylated rhBMP-2 (66 ± 17% of positive control) ( Figure 8 ). The activity of rhBMP-2 in the cell culture medium supernatant of DBBM was strongly decreased. This decrease was significantly higher for glycosylated (9 ± 4% activity of positive control) than for non-glycosylated rhBMP-2 (25 ± 8% activity of positive control) ( Figure 8 ). The activity of rhBMP-2 released from mPEG hydrogels having DBBM and rhBMP-2 incorporated was strongly decreased as well. The decrease was significantly higher for non-glycosylated (9 ± 3% activity of positive control) than it was for glycosylated rhBMP-2 (18 ± 3% activity of positive control) ( Figure 8 ).
Our aim was to understand the differences between the interaction of glycosylated and non-glycosylated rhBMP-2 with clinically evaluated bone substitute materials.
This analysis should ultimately allow for a combination of known materials and growth factors leading to an improved bone reconstruction. For our investigation we chose two well evaluated materials, mPEG hydrogels and DBBM. Both materials have previously been clinically tested for bone augmentation procedures in dentistry [7, 9, [25] [26] [27] [28] [29] [30] 32] .
We evaluated the equivalence of the two variants of rhBMP-2. In agreement with literature [9, [14] [15] [16] [17] , we found the biological activity of the glycosylated and nonglycosylated rhBMP-2 to be alike in vitro (   Figure 7 ). The biological activity of both variants drops rapidly in cell culture medium at 37 °C. This activity decrease has to be considered for rhBMP-2 delivery in vivo as well as for experimental design in vitro. Therefore, we compared all of our samples to a positive control of rhBMP-2 in cell culture medium. We further investigated equivalence of cell viability stimulated by the two variants of rhBMP-2. We observed a trend for an increase in cell viability in the presence of cell culture medium supernatant from preincubated bone substitute materials and/or glycosylated or nonglycosylated rhBMP-2 after 3 days and found a significant increase after 6 days PEGylation offers a great possibility to increase solubility and half-life of BMP-2 [35] or even allows for enzymatically controlled growth factor release [36] it should be avoided in order to deliver functional native rhBMP-2. Therefore, if applied together with an mPEG hydrogel, glycosylated rhBMP-2 is superior.
In contrast to the samples containing mPEG hydrogel, only a small part of the initial rhBMP-2 concentration can be detected in the cell culture medium supernatant of DBBM samples after 15 days of immersion. The amount of active rhBMP-2 detected in the cell culture medium supernatant is reduced to a corresponding amount. We attribute this effect to the high affinity of BMP-2 to hydroxyapatite-based materials [37] as well as to the high surface area (79.7 m 2 /g) of DBBM due to its micro-and nano-structure [38] . Moreover, instead of the expected release after immersion of to hydroxyapatite is higher than the affinity of bovine serum albumin to hydroxyapatite [37] . The reduced activity of the supernatant, however, does not necessarily imply a reduced activity in vivo, as indicated by successful studies on the combination of DBBM and rhBMP-2 [9, 32, 39] . rhBMP-2 could be adsorbed to DBBM in an active or a denatured form, or it could be that it is reactivated upon release after the slow degradation of DBBM in vivo. The significantly stronger affinity of glycosylated rhBMP-2 to DBBM compared to the non-glycosylated variant seems to recommend the use of glycosylated rhBMP-2 if applied together with DBBM.
However, Brown et al. have shown in vivo that an initially high concentration of rhBMP-2 followed by a slow release is favourable over a slow release only [19] . This fact together with the much lower production costs for the expression of rhBMP-2 in E.coli makes non-glycosylated rhBMP-2 the preferred protein if applied together with DBBM. In the sole clinical trial where DBBM was used as carrier for non-glycosylated rhBMP-2 the results show that overall bone formation was not increased compared to DBBM alone but maturation of bone as well as direct coverage of DBBM by bone had advanced significantly [32] . Both results suggest that non-glycosylated rhBMP-2 delivered by DBBM is still active but the long range effect is limited due to the high affinity of rhBMP-2 to DBBM. Whether this remaining activity is due to the low amount of rhBMP-2 dissolved in the extracellular matrix, rhBMP-2 resolubilized after the slow dissolution of DBBM in vivo or rhBMP-2 adsorbed to DBBM cannot be determined based on these results.
Combining the two previously discussed materials we Incorporated rhBMP-2 into mPEG hydrogels together with DBBM. This led to a constantly low concentration of rhBMP-2 in the cell culture medium supernatant during the 15 days of incubation, with a small increase after three days. After 15 days, in contrast to the samples with DBBM alone, a significantly higher concentration of glycosylated compared to non- 
Conclusions
We have shown that mPEG hydrogels interact with rhBMP-2 and reduce its activity.
Furthermore, we found a strong affinity of rhBMP-2 to DBBM. Based on these results
we question the use of mPEG hydrogels as a carrier-system for rhBMP-2 in conjunction with DBBM, since the use of DBBM with preadsorbed rhBMP-2 alone yields a higher BMP activity, which might translate to better results in vivo. Since the affinity of non-glycosylated rhBMP-2 to DBBM is lower than the affinity of the glycosylated variant, non-glycosylated rhBMP-2 may be used if an initial high concentration of rhBMP-2 is desired to attract cells chemotactically. Further research on this aspect is necessary to determine if rhBMP-2 adsorbed to DBBM and hydroxyapatite in general is active or denatured and/or released in an active form during degradation. However if other needs, e.g. formability or stability of the bone substitute require the use of mPEG hydrogels, glycosylated rhBMP-2 is the preferred growth factor since its interactions with mPEG hydrogels is significantly lower compared to non-glycosylated rhBMP-2. Figure 1 : Scheme of experimental setups. Glycosylated and non-glycosylated rhBMP-2 was incorporated into mPEG hydrogels, adsorbed to DBBM and incorporated into an mPEG hydrogel together with DBBM. These samples were immersed in cell culture medium to investigate concentration and activity in the supernatant over time. In order to separate effects derived from the adsorption or incorporation procedures, controls devoid of rhBMP-2 were prepared and immersed in cell culture medium that was subsequently supplemented with rhBMP-2. Empty controls without rhBMP-2 were prepared in order to evaluate the effect of the bone substitute material degradation products on cell viability. The low biological half-life
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